Patient Rating:

No Rating Available?

Adam M. Spivak, M.D.

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 585-2031 University Hospital
Infectious Diseases, Clinic 1A
50 N Medical Dr
Salt Lake City, UT 84132
Map

Bio

Dr. Spivak joined the Division of Infectious Diseases as a Visiting Instructor in the fall of 2011. He cares for HIV patients as a member of the Clinic 1A staff at the University of Utah Hospital and attends on the inpatient Infectious Diseases consult service at both the University and VA Hospitals.

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor
Academic Divisions Infectious Diseases
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Infec Disease)

Academic Profile

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor
Academic Divisions Infectious Diseases
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Infec Disease)

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 581-8812 School of Medicine
Infectious Diseases
30 N Medical Dr
Salt Lake City, UT 84132

Academic Bio

Dr. Spivak joined the Division of Infectious Diseases in October 2011 after completing Infectious Diseases fellowship training at Johns Hopkins University School of Medicine. His primary focus is on translational research exploring HIV persistence and strategies for viral eradication.

During fellowship, Dr. Spivak spent three years in the laboratory of Dr. Robert Siliciano where he studied cellular reservoirs of HIV and helped to run a pilot clinical trial of a novel HIV eradication strategy. In May 2011, Dr. Spivak was awarded a Bill and Melinda Gates Foundation Grand Challenges Explorations Grant for a research proposal describing an in vitro screening assay to identify compounds able to selectively induce apoptosis in HIV infected cells.

At the University of Utah, Dr. Spivak will spend the majority of his time in the laboratory of Vicente Planelles in the Department of Pathology. Working with members of the Planelles lab, he will continue his ongoing research into the nature of HIV persistence. He cares for HIV patients as a member of the Clinic 1A staff at the University of Utah Hospital and attends on the inpatient Infectious Diseases consult service at both the University and VA Hospitals.

Education

Education History

Type School Degree
Fellowship Johns Hopkins University School of Medicine
Infectious Diseases
Fellow
Chief Resident Johns Hopkins University School of Medicine
Internal Medicine
Chief Resident
Residency Johns Hopkins University School of Medicine
Internal Medicine
Resident
Internship Johns Hopkins University School of Medicine
Internal Medicine
Intern
Professional Medical University of Maryland School of Medicine
Medicine
M.D.
Undergraduate Princeton University
English Literature
A.B.

Publications

Selected Provider Publications

Journal Article

  1. A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy.Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R 3rd, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG (2014). A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy. Clin Infect Dis.
  2. Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration.Weil AF, Ghosh D, Zhou Y, Seiple L, McMahon MA, Spivak AM, Siliciano RF, Stivers JT (2013). Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc Natl Acad Sci U S A, 110(6), E448-57.
  3. Urinary Tract Infections: Current and Emerging Management Strategies.Barber AE, Norton JP, Spivak AM, Mulvey MA (2013). Urinary Tract Infections: Current and Emerging Management Strategies. Clin Infect Dis.
  4. Short Communication: Dynamic Constraints on the Second Phase Compartment of HIV-Infected Cells.Spivak AM, Rabi SA, McMahon MA, Shan L, Sedaghat AR, Wilke CO, Siliciano RF (2011). Short Communication: Dynamic Constraints on the Second Phase Compartment of HIV-Infected Cells. AIDS Res Hum Retroviruses, 27(7), 759-61.
  5. Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy.Gaillard S, Dinoso JB, Marsh JA, Dezern AE, OConnell KA, Spivak AM, Alwood K, Durand CM, Ambinder RF, Blankson JN (2011). Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. J Clin Virol, 51(3), 195-8.
  6. Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors.Spivak AM, Salgado M, Rabi SA, OConnell KA, Blankson JN (2011). Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors. J Virol, 85(19), 10399-403.
  7. A case of seronegative HIV-1 infection.Spivak AM, Brennan TP, OConnell KA, Sydnor E, Williams TM, Siliciano RF, Gallant JE, Blankson JN (2010). A case of seronegative HIV-1 infection. J Infect Dis, 201(3), 341-5.

Review

  1. Seronegative HIV-1 infection: a review of the literature.Spivak AM, Sydnor ER, Blankson JN, Gallant JE (2010). Seronegative HIV-1 infection: a review of the literature. [Review]. AIDS, 24(10), 1407-14.
  2. Spinal epidural abscess: current diagnosis and management.Pradilla G, Nagahama Y, Spivak AM, Bydon A, Rigamonti D (2010). Spinal epidural abscess: current diagnosis and management. [Review]. Current Infectious Disease Reports, 12(6), 484-91.

Letter

  1. Using highly active antiretroviral therapy to decrease perioperative HIV-1 transmission risk.Spivak AM, Siliciano RF (2010). Using highly active antiretroviral therapy to decrease perioperative HIV-1 transmission risk [Letter to the editor]. AIDS, 24(10), 1603-404; author reply 1604.

Poster

  1. Spivak AM, Andrade A, Hoh R, Bacchetti P, Eisele E, Buckheit III R, Lai J, Siliciano J, Siliciano R, Deeks S (2012). Safety and Feasibility of Using Disulfiram to Enhance HIV Transcription among Long-term ARV-treated Adults: Preliminary Results from a Pilot Study. Poster session presented at 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
  2. Spivak AM, Gaillard S, Dinoso J, Marsh J, Blankson J (2011). Sustained Elite Suppression of Replication Competent HIV-1 in a Patient Treated with Rituximab Based Chemotherapy. [Abstract 291]. Poster session presented at 18th CROI, Boston, MA.
  3. Spivak AM, Reza A, McMahon M, Sedaghat A, Siliciano RF (2009). Understanding Decay of Viremia in Patients on Raltegravir. . [Abstract 552]. Poster session presented at 16th CROI, Montreal, Canada.

Clinical Trials

Video & News

Video